Transthyretin Cardiomyopathy (ATTR-CM)

SNMMI currently offers several educational activities and resources designed to educate nuclear medicine physicians, cardiologists, technologists, and trainees on more accurately diagnosing and managing ATTR-CM using non-invasive nuclear cardiology imaging techniques. 

On-Demand Educational Activities

New! Educational Vignettes

SNMMI has produced a series of educational vignettes* on more accurately diagnosing and managing ATTR-CM. These short video vignettes will supplement the innovative educational programing currently being offered, educating the nuclear medicine community on the necessary background and practical skills for acquisition and interpretation of nuclear scans for diagnosis of ATTR-CM. 

Vignette #1: What is Amyloidosis?

Coming Soon!
  • Vignette #2: Cardiac Amyloidosis: Who is Affected?
  • Vignette #3: Cardiac Amyloidosis: Evaluating Patients with Suspected Cardiac Amyloidosis

The Journal of Nuclear Medicine (JNM)

Added value of SPECT/CT compared to SPECT in99mTc-PYP cardiac ATTR amyloidosis imaging
Kenneth NicholsSe-Young Yoon and Christopher Palestro

Uzair MahmoodMichael Feldkamp and Thomas Rosamond

Quantitative evaluation of 99mTc-pyrophosphate SPECT/CT in the diagnosis of transthyretin amyloid cardiomyopathy
Satoru Watanabe, Hiroto Yoneyama, Kenichi Nakajima, Hiroshi Wakabayashi, Anri Inaki, Junji Komatsu, Shohei Yoshida, Takahiro Konishi and Seigo Kinuya
Journal of Nuclear Medicine May 1, 2020, 61 (supplement 1) 1607;

3-D PYP Score for 3-hour uptake 99mTc Pyrophosphate SPECT-CT for Transthyretin Amyloid Cardiomyopathy
Ishan Garg, Andrew Hoffman, Martha Grogan, John Askew, Angela Dispenzieri, Steven Zeldenrust, Stephen Broski, Ann Packard and Geoffrey Johnson
Journal of Nuclear Medicine May 1, 2017, 58 (supplement 1) 35;

View The Journal of Nuclear Medicine (JNM) website for more results.

*The vignettes have been funded by a grant from Pfizer.